See every side of every news story
Published loading...Updated

Philanthropic partnership launches new initiative tackling antimicrobial resistance, the third-leading cause of death globally, by fast-tracking discovery of new treatments - AMR Insights

Summary by AMR Insights
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have launched the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment to combat antimicrobial resistance (AMR) caused by specific bacteria. The initiative will function as a consortium where funders, research institutions, and industry partners collaborate to drive innovation in developing new drugs. The Gr-ADI is part of a $300 million global health research…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

AMR Insights broke the news in on Friday, February 14, 2025.
Sources are mostly out of (0)